Unknown PHASE3 INTERVENTIONAL 4-arm NCT01224405

Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy (PON-PC-02)

Androgen Deprivation Withdrawal Versus Maintenance and Intermittent Chemotherapy Versus Continuous in Prostate Cancer Patients With Castrate Resistant Disease

Sponsor: University of Turin, Italy

Conditions Advanced Prostate Cancer

Interventions Continuous Docetaxel Docetaxel Docetaxel + LH-RH analogues

Updated 6 times since 2017 Last updated: Oct 19, 2010 Started: Apr 30, 2010 Primary completion: Aug 31, 2010 Completion: Apr 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Advanced Prostate Cancer and is currently ongoing. University of Turin, Italy leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE3

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Turin, Italy

Data source: University of Turin, Italy

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alba, Italy , Asti, Italy , Biella, Italy , Bologna, Italy , Candiolo (Torino), Italy , Casale Monferrato, Italy , Cremona, Italy , Cuneo, Italy , Garbagnate Milanese, Italy , Ivrea, Italy and 18 more locations